内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

ADARx Pharmaceuticals, Inc.

ADRX · Nasdaq · CIK 0001802369 · Healthcare · Biotechnology

内部人信号

90.6 / 100

5 位买方 · 11 条买入交易行 · $67.6M 买入总额

为什么有这个信号？

买方广度较强
买入规模较强
角色中等
近期性中等
确信度较强
评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+35.0 / 35
买入规模+24.4 / 25
角色+14.0 / 20
近期性+7.2 / 10
确信度+10.0 / 10

哪些因素限制了当前分数？

  • ⚠ 角色得分低 · 买入者中职位最高的是：TenPercentOwner（CEO、董事长和持股 10% 以上的股东得分最低）
  • ✓ Cluster breadth is broad · 4+ insiders
  • ✓ Recent activity · latest purchase 2026-09-28

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
Chimovits ErezDirector
○●
GORDON CARL LDirector,TenPercentOwner
○●
ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.Director,TenPercentOwner
○●
SR ONE CAPITAL MANAGEMENT, LLCTenPercentOwner
○●
George SimeonDirector,TenPercentOwner
○●
LAV Biosciences Fund V, L.P.; LAV Fund VI Opportunities, L.P.; LAV Fund VI, L.P.TenPercentOwner
○
● 买入▼ 卖出○ 其他

—

买方广度与集中度

合资格买方5
买入集中度25%最大买方： SR ONE CAPITAL MANAGEMENT, LLC · $17.1M
聚集买入 · 15天5 insiders峰值活动： 2026-09-28–2026-09-28

Roles in the peak window: Director, Director,TenPercentOwner, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

90.6 / 100

最新留档分数

↓ -0.2 pts相对上一个留档快照
  1. 91.2
  2. 91.1
  3. 91.0
  4. 90.8
  5. 90.6

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

11买入
0卖出
37其他 Form 4 交易行
6SEC 申报 · 365天
买入11 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他37 exercise / withholding / award / gift / other lines
10b5-1／计划交易Unavailable

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
—
3M
—
6M
—
12M
—

波动率与流动性

波动率
—
Beta
—
平均每日成交额
—

估值

市值
—
P/E
—

基本面

利润率
—
ROE
—
细分行业
Biotechnology

市场数据

价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
1,163,375
上期报告
0
日均成交量
669,771
回补天数
1.7

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.买入 (P)Common Stock950,000USD 17.00USD 16,150,000SEC 申报 ↗
2026-09-28GORDON CARL L买入 (P)Common Stock950,000USD 17.00USD 16,150,000SEC 申报 ↗
2026-09-28Chimovits Erez买入 (P)Common Stock61,516USD 17.00USD 1,045,772SEC 申报 ↗
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC买入 (P)Common Stock1,007,407USD 17.00USD 17,125,919SEC 申报 ↗
2026-09-28George Simeon买入 (P)Common Stock1,007,407USD 17.00USD 17,125,919SEC 申报 ↗

Form 4 申报证据

48 transaction lines in the latest 365-day window; 48 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.买入 (P)Common Stock950,000USD 17.00USD 16,150,000SEC 申报 ↗
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.C (C)Common Stock23,255,789USD —USD —SEC 申报 ↗
2026-09-28GORDON CARL L买入 (P)Common Stock950,000USD 17.00USD 16,150,000SEC 申报 ↗
展开近期 Form 4 证据 (11 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.买入 (P)Common Stock950,000USD 17.00USD 16,150,000SEC 申报 ↗
2026-09-28ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC; OrbiMed Israel GP II, L.P.C (C)Common Stock23,255,789USD —USD —SEC 申报 ↗
2026-09-28GORDON CARL L买入 (P)Common Stock950,000USD 17.00USD 16,150,000SEC 申报 ↗
2026-09-28GORDON CARL LC (C)Common Stock23,255,789USD —USD —SEC 申报 ↗
2026-09-28Chimovits Erez买入 (P)Common Stock61,516USD 17.00USD 1,045,772SEC 申报 ↗
2026-09-28Chimovits ErezC (C)Common Stock9,230,509USD —USD —SEC 申报 ↗
2026-09-28SR ONE CAPITAL MANAGEMENT, LLC买入 (P)Common Stock1,007,407USD 17.00USD 17,125,919SEC 申报 ↗
2026-09-28SR ONE CAPITAL MANAGEMENT, LLCC (C)Common Stock8,336,661USD —USD —SEC 申报 ↗
2026-09-28LAV Biosciences Fund V, L.P.; LAV Fund VI Opportunities, L.P.; LAV Fund VI, L.P.C (C)Common Stock11,550,917USD —USD —SEC 申报 ↗
2026-09-28George Simeon买入 (P)Common Stock1,007,407USD 17.00USD 17,125,919SEC 申报 ↗
2026-09-28George SimeonC (C)Common Stock8,336,661USD —USD —SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码ADRX
CIK0001802369
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所Nasdaq

数据覆盖

本地 Form 4 历史48 transaction lines from 2026-09-28 to 2026-09-28
11 P purchase lines · 0 S sale lines · 37 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.